Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511302 · ClinicalTrials.gov registry record · Phase 1
Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma
A Phase 1 study, sponsored by Revalesio Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT01511302 is a Phase 1 study that has completed, run by Revalesio Corporation. The registered enrollment target is 65 participants.
The verdict
NCT01511302, a Phase 1 study, has completed, sponsored by Revalesio Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether RNS60, in combination with budesonide, is safe in mild to moderate asthmatics when taken by nebulization over a 28-day period, compared to a 28-day control period.
Interventions
- DRUG Normal Saline
- DRUG Budesonide
- DRUG RNS60
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511302
The ClinicalTrials.gov registry entry for NCT01511302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revalesio Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Normal Saline is the first listed.
NCT01511302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01511302 about?
NCT01511302 is a clinical study titled "Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma". The purpose of this study is to determine whether RNS60, in combination with budesonide, is safe in mild to moderate asthmatics when taken by nebulization over a 28-day period, compared to a 28-day control period.
What is the current status of trial NCT01511302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2012-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01511302?
The interventions under investigation include: Normal Saline (DRUG), Budesonide (DRUG), RNS60 (DRUG).
Who is sponsoring clinical trial NCT01511302?
This trial is sponsored by Revalesio Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.